Skip to contentC
Collegium Pharmaceutical, Inc
C
COLLCollegium Pharmaceutical, Inc Q4 2024 · 10-K
Revenue$181.95M$181.95M+21.5% vs Q4 2023 Net Income$12.54M$12.54M−60.8% vs Q4 2023 EPS Diluted$0.36$0.36−56.1% vs Q4 2023 Gross Profit$98,288,000+3.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Collegium Pharmaceutical, Inc · CIK 1267565 · Engraved from SEC EDGAR
Operating Cash Flowderived$84,644,000+15.4% Free Cash Flowderived$84,074,000+14.9% Margins · derivedGross margin54.0%−9.2 pt vs Q4 2023
Operating margin20.9%−20.2 pt vs Q4 2023
Net margin6.9%−14.4 pt vs Q4 2023
ended Dec 31, 2024 · filed Feb 27, 2025 · 58 d after period end